Etelcalcetide hydrochloride (Parsabiv ® , ONO-5163/AMG 416) is an allosteric modulator of the calcium (Ca)-sensing receptor that was originally produced by KAI Pharmaceuticals Inc. (now Amgen Inc.). It has recently been approved as the first intravenous calcimimetic agent for secondary hyperparathyroidism (SHPT) in many countries. Etelcalcetide is an intravenous injectable drug that can be administered and eliminated through the dialysis circuit in chronic kidney disease patients. In the present study, we evaluated the in vitro pharmacological profile and in vivo parathyroid hormone (PTH)-and Ca-lowering activities of etelcalcetide in a rat 5/6 nephrectomy model of chronic renal insufficiency with SHPT. Etelcalcetide increased the intracellular Ca concentration in HEK-293T cells expressing human Ca-sensing receptor with an EC 50 value (95% confidence interval) of 0.53 μM (0.28-1.0 μM) and suppressed PTH secretion from rat parathyroid gland cells with 0.36 μM (0.24-0.54 μM) by activating Ca-sensing receptor. The specificity of etelcalcetide was evaluated by examining its ability to stimulate or inhibit radioligand binding to a panel of 34 off-target proteins. There were no significant changes in the presence of 10 μM etelcalcetide. Furthermore, in a rat 5/6 nephrectomy model of chronic renal insufficiency with SHPT, single intravenous administration of etelcalcetide at 0.3, 1.0, and 3.0 mg/kg decreased plasma PTH and serum Ca levels. Taken together, the present findings identify etelcalcetide as a calcimimetic with potent PTH-and Ca-lowering effects via Ca-sensing receptor agonist activity.
Introduction
Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease and end-stage renal disease that results in defective calcium (Ca) and phosphorus (P) homeostasis. In SHPT, excess amounts of parathyroid hormone (PTH) are constantly released from enlarged parathyroid glands, thereby elevating the blood levels of PTH, and the increased concentrations of circulating PTH are associated with abnormalities in serum Ca, P, and fibroblast growth factor 23 (Cunningham et al., 2011) . These biochemical changes worsen the progression of SHPT and are associated with abnormal bone histology, increased fracture risk, vascular and soft tissue calcification, and increased mortality (Joy et al., 2007) .
Cinacalcet hydrochloride is an allosteric activator of the Ca-sensing receptor that is orally administered once daily in end-stage renal disease patients with SHPT to decrease their PTH and Ca levels through its calcimimetic activity (Nemeth et al., 2004) . However, the utility of cinacalcet can be limited by gastrointestinal intolerability and drugdrug interaction mediated by drug-metabolizing enzymes. Specifically, with its CYP2D6 inhibitory effect, cinacalcet increased the AUC of dextromethorphan by approximately 11-fold when combined with dextromethorphan hydrobromide hydrate, a CYP2D6 substrate (Kyowa Hakko Kirin Co., Ltd., 2017). Thus, there was an unmet need for improved therapeutic agents (Walter et al., 2013) .
Etelcalcetide hydrochloride (Parsabiv next hemodialysis session because etelcalcetide is mainly cleared by dialysis Inoue and Harada, 2017) . Etelcalcetide, which is characterized by a D-amino acid peptide backbone, is gastrointestinal peptidolytic enzyme-resistant and insusceptible to metabolic enzymes such as cytochrome P450 . These features of etelcalcetide may allow physicians to manage and control PTH levels more effectively. Walter et al. reported the EC 50 of etelcalcetide as 25 μM in an in vitro signaling assay using intracellular inositol monophosphate in cells expressing human Ca-sensing receptor. In contrast, plasma etelcalcetide concentrations required to reduce plasma PTH concentration in 5/6 nephrectomized rats (1 mg/kg, Cmax after single intravenous administration) was 1.49 μM (Walter et al., 2013) , which was comparable to that in Japanese hemodialysis patients with SHPT (1.02 μM, 15 mg/ person clinically maximal dose, estimated Cmax after repeated intravenous administration) (Ono Pharmaceutical Co., Ltd., application dossier CTD 2. 6.2.6, 2016) . To clarify what caused the large discrepancy between in vitro and in vivo results, we evaluated in vitro Casensing receptor activity using two systems: an intracellular Ca concentration assay using human Ca-sensing receptor expressing cells and a PTH secretion assay using rat parathyroid gland primary culture cells. We also assessed the off-target selectivity of etelcalcetide for verifying its side effects. Furthermore, we attempted for the first time to elucidate in vivo PTH-and Ca-lowering activities of etelcalcetide after single intravenous administration using a rat 5/6 nephrectomy model of chronic renal insufficiency with SHPT.
Materials and methods

Chemicals and peptides
Etelcalcetide was synthesized by Bachem Americas, Inc. (Torrance, CA, USA) using a solid-phase peptide synthesis method based on the Fmoc strategy and purified in the hydrochloride salt form by highperformance liquid chromatography. It was characterized to have 98.4% purity, and its identity was confirmed by high-performance liquid chromatography and liquid chromatography/mass spectroscopy.
Intracellular Ca-sensing receptor signaling assay
HEK-293T cells stably expressing the human Ca-sensing receptor and their parental cells (Multispan Inc., Hayward, CA, USA) were seeded into 96-well plates (defined as measurement plates), and the culture medium was replaced with loading buffer (5 mg/l Fura-2AM, Hank's Balanced Salt Solution with Mg 2+ and Ca 2+ , 1.25 mM probenecid, 0.04% Pluronic F-127, 20 mM HEPES) at 100 μl/well. After approximately 1 h of incubation in a CO 2 incubator (37°C, 5% CO 2 , 95% air), the medium was gently removed and replaced with assay buffer (20 mM HEPES, 0.41 mM MgSO 4 , 0.49 mM MgCl 2 , 1 mM CaCl 2 , 1.25 mM probenecid) at 90 μl/well. The plates containing etelcalcetide were then set up in a fluorescence drug screening system (FDSS7000EX; Hamamatsu Photonics K.K., Hamamatsu, Japan), and the intracellular Ca-sensing receptor signaling assay was initiated. At approximately 2 min after initiation, a 10-μl aliquot per well was transferred from the etelcalcetide plates to the measurement plates, and the assay was continued for at least 60 min. The intracellular Ca concentration was determined by illuminating the cells with two-wavelength excitation light (340 nm and 380 nm) and monitoring the fluorescence intensity at 540 nm. The fluorescence intensity ratios before and after addition of etelcalcetide were analyzed by the FDSS7000EX system. EC 50 values were determined by curve-fitting of the intracellular Ca concentration data using GraphPad Prism Ver. 5.04 statistical analysis software (GraphPad Software Inc., San Diego, CA, USA).
PTH secretion assays
The effect of etelcalcetide on PTH secretion was assessed in primary cultures of dissociated rat parathyroid cells as previously described (Racke and Nemeth, 1993; Sakaguchi et al., 1987) . Under inhalation anesthesia with isoflurane (Mylan Seiyaku Ltd., Tokyo, Japan), rats were exsanguinated through the abdominal aorta. An incision was made in the skin of the throat and the immediate underlying muscle, and the thyroid glands attached to the trachea were excised together with the parathyroid glands. The parathyroid glands were removed from the thyroid glands under a microscope and immersed in a Liberase TL Research Grade solution (Roche Diagnostics K.K., Tokyo, Japan) for digestion. The digested parathyroid glands were pipetted for cell dispersion, and the dispersed cells were seeded into 96-well plates at 100 μl/well for overnight static culture in a CO 2 incubator (37°C, 5% CO 2 , 95% air). On the following day, the supernatant was replaced with 100 μl of medium containing vehicle or etelcalcetide, followed by static culture for 24 h in a CO 2 incubator (37°C, 5% CO 2 , 95% air). After the incubation, the supernatants were collected and measured for their PTH concentrations by enzyme-linked immunosorbent assay (ELISA) using Rat BioActive Intact PTH ELISA Kit (Immutopics Inc., San Clemente, CA, USA).
Radioligand binding assay
The radioligand binding assays were conducted by Ricerca Biosciences LLC (Concord, OH, USA). To check the selectivity of etelcalcetide, we selected 34 targets including the Ca-sensing receptor related family listed in Table 1 . Radioligand binding assays were conducted with 10 μM etelcalcetide for quantification of the stimulatory or inhibitory effect of etelcalcetide on the target proteins. Assays were independently validated with a reference standard for each target. A significant response was defined as an effect of etelcalcetide to stimulate or inhibit maximal binding of the radioligand by > 50%.
Animals
The study used male Sprague-Dawley rats (N = 44) with partial nephrectomy (5/6 nephrectomized rats) supplied by Japan SLC Inc. (Tokyo, Japan). Specifically, the rats were 5 weeks of age when the model was prepared (2/3 left nephrectomy at 4 weeks of age and total right nephrectomy at 5 weeks of age), 6 weeks of age when delivered, and 9 weeks of age when used in the study. The 5/6 nephrectomized rats were individually housed in single cages (W 180 mm × L 270 mm × H 180 mm). Upon delivery, the rats were provided with a high P diet (powdered feed containing 1.0% P and 0.9% Ca; CLEA Japan Inc., Tokyo, Japan) and tap water (automatic water dispenser) ad libitum. Excrement was disposed of by an automated cleaning system. While on the high P diet, the animals were observed for their general condition, and their body weight and food consumption were measured. Animals with no abnormalities were used (n = 42, two animals were excluded from this experiment and euthanized with anesthesia because of hematuria). Based on the national regulations and guidelines, all animal experiments were reviewed by our Institutional Animal Care and Use Committee and finally approved by the director of the research institution. The animal experiments were performed in accordance with the Regulations for Animal Experiments of Ono Pharmaceutical Co., Ltd.
Assignment of test animals to groups
To ensure the absence of any inter-group bias in plasma creatinine concentration, plasma PTH concentration, serum Ca concentration, and plasma P concentration on the day before the administration of etelcalcetide (3 weeks after the start of high P diet), the animals were grouped by stratified randomization using SAS 9.2 TS2M3 (SAS Institute Japan) and its associated system EXSUS Ver. 7.7.1 (CAC EXICARE Corporation). Animals were allocated to 4 groups of 8 animals each, and surplus animals (n = 10) were euthanized with anesthesia.
2.7. Administration of etelcalcetide or vehicle, blood sampling, and preparation of plasma and serum samples Etelcalcetide (0.3, 1, and 3 mg/kg) or vehicle was administered at 2 ml/kg via the jugular vein with the animals under isoflurane inhalation anesthesia (n = 8 per group). Approximately 600 μl of blood was drawn via the jugular vein under isoflurane inhalation anesthesia on the day before administration and at 1, 6, 24, and 48 h postdose. After the blood withdrawal at 48 h postdose, the animals were exsanguinated via the abdominal aorta. Approximately 150 μl of each blood sample was allowed to stand at room temperature for at least 1 h and then centrifuged at 4°C for 5 min at 10,000 G to obtain serum. The remaining blood was dispensed into blood sampling tubes containing dipotassium ethylenediaminetetraacetic acid (Becton-Dickinson Japan, Tokyo, Japan) and centrifuged at 4°C for 5 min at 10,000 G to obtain plasma. The obtained serum and plasma samples were stored on ice until analysis. If not measured on the sampling day, the samples were stored at − 80°C. The samples collected on the day before administration were analyzed for plasma PTH, serum Ca, plasma P, and plasma creatinine concentrations for grouping. The samples collected at 1, 6, 24, and 48 h postdose were analyzed for plasma PTH, serum Ca, and plasma P concentrations.
Plasma and serum analysis
Plasma PTH concentrations were determined by ELISA using Rat BioActive Intact PTH ELISA Kit in accordance with the manufacturer's instructions (quantification range: 34.0-3160.0 pg/ml). The samples were diluted at a given dilution ratio with a stock solution or the accompanying diluent, and the absorbance was measured in duplicate using a microplate reader (Spectra Max™ M5e; Molecular Devices LLC, Sunnyvale, CA, USA). If the measured value of the sample stock solution was below the lower limit of quantification, the PTH concentration for that sample was assumed to be 34.0 pg/ml. Serum Ca concentrations were determined by colorimetry using QuantiChrom™ Calcium Assay Kit (BioAssay Systems, Hayward, CA, USA) in accordance with the manufacturer's instructions (quantification range: 2.00-20.00 mg/dl). The absorbance of the sample stock solution was measured in duplicate using the microplate reader. Plasma creatinine concentrations were determined by colorimetry using L type Wako CRE·M Enzyme Colorants A and B and Multi-calibrator A (Wako Pure Chemical Industries Ltd., Tokyo, Japan) in accordance with the manufacturer's instructions (quantification range: 0.048-100.00 mg/dl). The absorbance of the sample stock solution was measured once using Hitachi 7080 Autoanalyzer (Hitachi High-Technologies Corporation, Tokyo, Japan). Plasma P concentrations were determined by colorimetry using L type Wako inorganic phosphorus enzyme solution, substrate solution, and Multi-calibrator A (Wako Pure Chemical Industries Ltd., Tokyo, Japan) in accordance with the manufacturer's instructions (quantification range: 0.29-40.00 mg/dl). The absorbance of the sample stock solution was determined by single analysis using Hitachi 7080 Autoanalyzer.
Statistical analysis
Nonlinear regression analyses were performed with GraphPad Prism Ver. 5.04 software to determine the EC 50 values and prepare the figures. Other data processing was performed using Microsoft Office Excel 2007 SP1 software (Microsoft Corporation, Redmond, WA, USA). Relative plasma PTH concentrations, means, and standard errors were calculated by Microsoft Office Excel 2010 SP1 software. Significance tests were performed with SAS 9.2 TS2M3 software (SAS Institute Japan Ltd., Tokyo, Japan) and its associated EXSUS Ver. 7.7.1 operating system (CAC EXICARE Corporation, Tokyo, Japan). Relative plasma PTH concentrations, serum Ca concentrations and plasma P concentrations in the control group and etelcalcetide groups were compared at each time point by t-tests using a stepdown closed testing procedure, starting from the highest etelcalcetide dose. All tests were two-sided, with a nominal significance level of 5%.
Results
Etelcalcetide has an agonist activity of the Ca-sensing receptor
The structure of etelcalcetide is shown in Fig. 1 . To determine the Ca-sensing receptor agonist activity of etelcalcetide, we measured intracellular Ca concentrations using a fluorescence drug screening system. As shown in Fig. 2 , etelcalcetide dose-dependently increased the Ca concentration in HEK-293T cells expressing the human Ca-sensing receptor with an EC 50 value (95% confidence interval) of 0.53 μM (0.28-1.0 μM) in the presence of 1.0 mM Ca but had no effect on untransfected HEK-293T cells. Furthermore, pretreatment with NPS-2143, an antagonist of the Ca-sensing receptor (Nemeth et al., 2001) , abolished the inhibitory effect of etelcalcetide (data not shown), indicating that the intracellular Ca accumulation in response to etelcalcetide was human Ca-sensing receptor-dependent. The Hill coefficient (95% confidence interval) was calculated to be 1.5 (0.35-2.6). The EC 50 value for Fig. 1 . Structure of etelcalcetide.
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Etelcalcetide inhibits PTH secretion from rat parathyroid cells
For the determination of the inhibitory effect of etelcalcetide on PTH secretion, primary parathyroid cells were prepared from normal rats and examined for their PTH secretion with and without etelcalcetide. The results are shown in Fig. 3 . Etelcalcetide inhibited PTH secretion from primary cultured rat parathyroid cells with an EC 50 value (95% confidence interval) of 0.36 μM (0.24-0.54 μM) in the presence of 1.0 mM Ca. The analysis yielded a Hill coefficient of 1.0, suggesting that etelcalcetide acts at a single binding site on the receptor (Corpeland, 2000) . These results were consistent with a previous report (Walter et al., 2013) .
Etelcalcetide does not bind to related receptors, ion channels, or norepinephrine transporter
The specificity of etelcalcetide was evaluated by examining its ability to stimulate or inhibit radioligand binding to a panel of 34 offtarget receptors, ion channels, and norepinephrine transporter. As shown in Table 1 , there were no significant changes in radioligand binding to any of the target proteins in the presence of 10 μM etelcalcetide.
Etelcalcetide decreases plasma PTH and serum Ca concentrations in a rat model of SHPT
The in vivo effects of single doses of etelcalcetide on plasma PTH and serum Ca concentrations were evaluated in a model of SHPT involving 5/6 nephrectomized rats fed a high P diet (see Table 2 for baseline biochemical characteristics). The effects of etelcalcetide on plasma PTH concentrations in these rats are shown in Fig. 4A and Table 3 . In all of three etelcalcetide groups, the relative plasma PTH concentrations at 1 and 6 h postdose were significantly lower than those in the control group. Moreover, the effect of 3 mg/kg etelcalcetide lasted until 24 h postdose.
The effects of etelcalcetide on serum Ca concentrations in the 5/6 nephrectomized rats fed a high P diet are shown in Fig. 4B and Table 4 . In the 1 and 3 mg/kg etelcalcetide groups, the serum Ca concentration at 1 h postdose was significantly lower than that in the control group, and the effects in these groups lasted until 48 h postdose.
The effects of etelcalcetide on the plasma P concentration in 5/6 nephrectomized rats fed a high P diet are shown in Fig. 4C and in Table 5 . In the 3 mg/kg etelcalcetide group, the plasma P concentration at 1 h postdose was significantly lower than that in the control group. On the other hand, in all of three etelcalcetide groups, the plasma P concentration at 6 h postdose was significantly higher than that in the control group. The effect lasted until 24 h postdose in the 3 mg/kg etelcalcetide group.
Discussion
In this study, we characterized the pharmacological potential of etelcalcetide by in vitro and in vivo approaches. The potency of etelcalcetide was evaluated by its dose-response relationships using the intracellular Ca concentration, a well-known indicator of Ca-sensing receptor agonist activity established in a cinacalcet study (Nemeth et al., 2004) . In the present study, etelcalcetide increased the Ca concentration in cells stably expressing the human Ca-sensing receptor but did not increase the concentration in the parental cells. The effective dose of etelcalcetide is equivalent to that is required to reduce PTH concentration in patients with SHPT (Ono Pharmaceutical Co., Ltd., application dossier CTD 2.6.2.6, 2016). Furthermore, etelcalcetidemediated activation of the human Ca-sensing receptor in HEK-293T Fig. 2 . Effect of etelcalcetide on intracellular Ca concentrations in cells stably expressing human Ca-sensing receptor and their parental cells. Cells stably expressing human Ca-sensing receptor (circles) and parental cells (triangles) were treated with various concentrations of etelcalcetide, and the percent changes from baseline in the intracellular Ca concentrations after treatment were calculated. Data represent the mean and standard error for the percent changes in intracellular Ca concentration for three cycles. Fig. 3 . Effect of etelcalcetide on PTH secretion in primary cultured rat parathyroid cells. Primary cultured rat parathyroid cells were treated with various concentrations of etelcalcetide, and the PTH secretion rates were calculated by the resulting changes in PTH concentration. The PTH secretion rates for three plates (plate 1: circles; plate 2: triangles; plate 3: squares) are shown.
Table 2
Summary of baseline characteristics before administration in 5/6 nephrectomized rats fed a high P diet. Data are expressed as mean ± standard error (n = 8 per group).
K. Harada et al. European Journal of Pharmacology 842 (2019) 139-145 cells increased the intracellular concentration of inositol monophosphate, a downstream metabolite of second messenger inositol 1,4,5-trisphosphate that accumulates after Ca-sensing receptor activation (Walter et al., 2013) , but the effective concentration was higher than that in the intracellular Ca concentration assay. Importantly, the Casensing receptor agonist activity of etelcalcetide was abolished by pretreatment with NPS-2143, a Ca-sensing receptor antagonist, as previously reported (Nemeth et al., 2001) . Taking these findings together, we conclude that etelcalcetide exhibited human Ca-sensing receptor-specific agonist activity in our assay system. Changes in inositol monophosphate accumulation as well as intracellular Ca concentration provide a quantitative and functional assessment of Ca-sensing receptor activity in cells. However, the reason for the difference in the effective concentration between the two assay systems remains unclear. This is the first report that the observed suppression of PTH secretion by etelcalcetide was equivalent to that of cinacalcet in the same assay system using primary cultured rat parathyroid cells (Nemeth et al., 2004) . Furthermore, etelcalcetide inhibited PTH secretion from rat parathyroid glands (data not shown). These assay systems provide a better reflection of physiological conditions than Ca-sensing receptorexpressing cells, and its results are therefore important for discussing the in vivo effect of etelcalcetide. Indeed, the effective dose of etelcalcetide in our assay system is equivalent to that in patients and rat SHPT model (Ono Pharmaceutical Co., Ltd., application dossier CTD 2.6.2.6, 2016; Walter et al., 2013) . These results provide valuable data to verify that etelcalcetide inhibits PTH secretion from parathyroid cells through Ca-sensing receptor activation.
In the radioligand binding assays using a panel of 34 off-target proteins, 10 µM etelcalcetide did not show significant binding to any of the target proteins, indicating no binding affinity for these targets. A previous report on the target activity and specificity of etelcalcetide revealed a unique mechanism of action, involving thiol-disulfide exchange between the N-terminal D-cysteine of etelcalcetide and cysteine 482 in the extracellular domain of the Ca-sensing receptor (Alexander et al., 2015) . Importantly, other members of the class C G-protein coupled receptor family to which Ca-sensing receptor belongs do not share a cysteine in the homologous protein region (Alexander et al., 2015) . Therefore, the uniqueness of cysteine 482 to the Ca-sensing receptor supports the high selectivity of etelcalcetide for the Ca-sensing receptor.
Our model animals, 5/6 nephrectomized rats, fed a high P diet had a mean plasma PTH concentration of approximately 1000 pg/ml on the day before etelcalcetide administration, which is ten times higher than that in normal rats. The mean plasma creatinine concentration in 5/6 nephrectomized rats fed a high P diet was approximately 0.5 mg/dl on the day before administration, which is higher than that in normal rats. Thus, our model animals are considered to reflect the pathology of chronic renal insufficiency with SHPT (Carrillo-López et al., 2010) . After administration of etelcalcetide, the plasma PTH concentration and serum Ca concentration were lower than those in the control group. The effect of 3 mg/kg etelcalcetide on the plasma PTH concentration lasted until 24 h postdose, while the effect on the serum Ca concentration lasted until 48 h postdose. These findings suggest that etelcalcetide lowers the plasma PTH concentration, thereby inhibiting Ca release from bone and lowering the serum Ca concentration. Similar to the case for the plasma PTH concentration in the present study, etelcalcetide was previously reported to decrease the serum Ca concentration in normal dogs, a rat model of acute renal insufficiency, and a rat model of chronic renal insufficiency (Alexander et al., 2015; Walter et al., 2013 Walter et al., , 2014 . On the other hand, etelcalcetide exhibited the biphasic effect on the plasma P concentration. Reportedly, PTH has the physiological Fig. 4 . Effect of etelcalcetide on plasma PTH and serum Ca concentrations in 5/ 6 nephrectomized rats fed a high P diet. (A) The relative plasma PTH concentrations (percentage changes relative to plasma PTH concentration on day before administration) are expressed as mean ± standard error (control: black bars, n = 8; etelcalcetide 0.3 mg/kg: white bars, n = 8; etelcalcetide 1 mg/kg: light grey bars, n = 8; etelcalcetide 3 mg/kg: dark grey bars, n = 8). *** P < 0.001 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group). (B) The serum Ca concentrations (mg/dl) are expressed as mean ± standard error (control: black bars, n = 8; etelcalcetide 0.3 mg/kg: white bars, n = 8; etelcalcetide 1 mg/kg: light grey bars, n = 8; etelcalcetide 3 mg/kg: dark grey bars, n = 8). * P < 0.05, *** P < 0.001 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group). (C) The plasma P concentrations (mg/dl) are expressed as mean ± standard error (control: black bars, n = 8; etelcalcetide 0.3 mg/kg: white bars, n = 8; etelcalcetide 1 mg/kg: light grey bars, n = 8; etelcalcetide 3 mg/kg: dark grey bars, n = 8). * P < 0.05, ** P < 0.01, * ** P < 0.001 (versus control group by a ttest, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group). effect of stimulating P mobilization from bone but of inhibiting renal tubular re-absorption of P (Nagano et al., 2012) . Thus, the decrease in plasma P concentration found at 1 h postdose in the 3 mg/kg etelcalcetide group appears to be the result of inhibited P mobilization from bone. Further, the later increase in plasma P concentration by the administration of etelcalcetide can be attributed to stimulated re-absorption of P due to the reduction in plasma PTH concentration by etelcalcetide. On the other hand, etelcalcetide reduces plasma P concentration in SHPT patients on dialysis (Martin et al., 2014) . We attribute the observed difference in the disposition of plasma P to the differences in residual renal function between SHPT patients and the condition in this rat disease model. The effect on P by cinacalcet, an existing Ca-sensing receptor agonist, has also been reported to be different in nonclinical and clinical applications (Nagano et al., 2012) . It thus appears that the effect of etelcalcetide on plasma P concentration in rat models of this condition is hardly extrapolatable to SHPT patients (Ono Pharmaceutical Co., Ltd., application dossier CTD 2.6.2.6, 2016).
In the present study, a single intravenous administration of etelcalcetide resulted in a rapid and sustained decrease in plasma PTH concentration with the duration of PTH suppression being dose-dependent. Furthermore, it is reported that the prolonged suppression of plasma PTH by chronic administration of etelcalcetide prevented vascular calcification and preserved bone structure and bone strength in rat SHPT models Li et al., 2017) . These results of etelcalcetide are in line with the previous report obtained in the use of cinacalcet and calcimimetics compounds in preclinical models (Kawata et al., 2008; Wada et al., 1998) or in clinical studies with cinacalcet (Raggi et al., 2011; Behets et al., 2015) . Thus, our study supports the potent PTH-and Ca-lowering effects observed after clinical use of etelcalcetide and identifies etelcalcetide as a novel calcimimetic that exerts its efficacy via Ca-sensing receptor agonist activity. To date, some clinical trials and basic research studies of etelcalcetide have been conducted (Block et al., 2017; Fukagawa et al., 2017; Li et al., 2017; Shigematsu et al., 2018; Yokoyama et al., 2017a Yokoyama et al., , 2017b . However, further studies are needed to assess its pharmacological outcomes, especially bone abnormalities, vascular and soft tissue calcification, and mortality. In addition, because the binding mode of etelcalcetide differs from that of cinacalcet, clarification of its intracellular signaling pathways may provide further insights. We hope that the differences between etelcalcetide and cinacalcet will be verified by further accumulation of nonclinical and clinical evidence.
With its high specificity avoiding off-target molecules and low central penetration (Walter et al., 2013) , etelcalcetide is expected to reduce the side effects, including gastrointestinal symptoms, associated with the oral agent cinacalcet. Furthermore, etelcalcetide may provide not only better patient compliance but also a prolonged and consistent PTH reduction through intravenous administration by hemodialysis compared with an oral agent. We anticipate that etelcalcetide as a new treatment option provides benefits to hemodialysis patients with SHPT. Data are expressed as mean ± standard error (n = 8 per group).
Table 4
Effect of etelcalcetide on serum Ca concentrations in 5/6 nephrectomized rats fed a high P diet. Data are expressed as mean ± standard error (n = 8 per group). a P < 0.05 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group). c P < 0.001 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group).
Table 5
Effect of etelcalcetide on plasma P concentrations in 5/6 nephrectomized rats fed a high P diet. Data are expressed as mean ± standard error (n = 8 per group). a P < 0.05 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group). b P < 0.01 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group). c P < 0.001 (versus control group by a t-test, stepdown closed testing procedure starting from the etelcalcetide 3 mg/kg group).
